A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Ophthalmology,General Medicine
Reference34 articles.
1. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting;Boulanger-Scemama;J Fr Ophtalmol,2015
2. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients;Ehlken;Clin Ophthalmol,2017
3. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey;Varano;Clin Ophthalmol,2015
4. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review;Okada;Ophthalmology,2021
5. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration;Boyer;Ophthalmology,2009
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Using a Smartphone-Based Chatbot for Postoperative Care After Intravitreal Injection During the COVID-19 Pandemic: Retrospective Cohort Study;JMIR Formative Research;2024-08-02
2. Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group;Indian Journal of Ophthalmology;2024-07-29
3. Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-07-12
4. Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER;Ophthalmology Retina;2024-07
5. The neuroprotective effect of human primary astrocytes in multiple sclerosis: In vitro model;PLOS ONE;2024-04-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3